Waters Corporation (WATERS CORP) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2003. Waters Corporation is the world's largest manufacturer and distributor of high performance liquid chromatography (HPLC) instruments, chromatography columns, and related services. Through its subsidiaries, it also leads in mass spectrometry (Micromass) and thermal analysis (TA Instruments). The company aggregates these three operating segments into one reporting segment.
Key Financial Metrics
Revenue and Profit (Six Months Ended June 30, 2003):
- Net Sales: $452.8 million (up 8% from $417.5 million in 2002).
- Gross Profit: $263.1 million (Gross margin of 58.1%, up 10 basis points from 58.0% in 2002).
- Operating Income: $95.6 million (up 4% from $91.6 million in 2002).
- Net Income: $76.1 million (up 11% from $68.4 million in 2002).
- Diluted EPS: $0.59 (up from $0.50 in 2002).
Liquidity and Balance Sheet (As of June 30, 2003):
- Cash and Cash Equivalents: $283.0 million.
- Total Current Assets: $616.8 million.
- Total Current Liabilities: $376.0 million.
- Debt: $115.8 million outstanding under a $250.0 million credit facility (primarily to fund share repurchases).
- Stockholders' Equity: $605.0 million.
Cash Flow (Six Months Ended June 30, 2003):
- Operating Cash Flow: $49.9 million provided.
- Investing Cash Flow: $12.1 million provided (driven by the release of $49.9 million in restricted cash).
- Financing Cash Flow: $48.2 million used (primarily for $167.5 million in stock repurchases).
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 5% growth in HPLC sales and strong growth in thermal analysis. Mass spectrometry sales declined approximately 20% due to weakness in high-end Q-Tof products and the pharmaceutical drug discovery market.
- Margin Expansion: Gross margin improved due to favorable foreign currency translation, a higher mix of consumable/service sales, and supply chain cost reductions.
- One-Time Charges: The six-month period included a $5.0 million loss on the disposal of the inorganic mass spectrometry product line and $1.2 million in restructuring charges related to the integration of Micromass and HPLC sales organizations.
- Debt Position: The company moved from no debt to $115.8 million in borrowings to finance an aggressive share repurchase program.
- Restricted Cash: $49.9 million in restricted cash held at year-end 2002 was released in April 2003 following the settlement of the Applera patent litigation.
Guidance, Outlook, and Risks
Management Commentary: Management notes that trends in pharmaceutical spending remain weak, particularly in drug discovery labs, negatively impacting high-end mass spectrometry sales. However, HPLC consumables and service sales continue to grow in low double-digits. The company expects capital expenditures to remain similar in the second half of 2003.
Significant Risks and Contingencies:
- Patent Litigation (Applera): The company paid $53.7 million in April 2003 to settle damages and interest regarding the Quattro Ultima mass spectrometer. While the U.S. case is settled, similar claims exist in Japan and Canada with uncertain outcomes.
- Patent Litigation (Hewlett-Packard): Ongoing litigation in Germany, France, and England regarding the "Alliance" pump. The company has lost appeals in England and France and is appealing a German decision.
- Environmental Settlement: In July 2003 (subsequent to the period end), the company settled an environmental matter with the Commonwealth of Massachusetts for a $5.9 million penalty plus $0.6 million in supplemental projects.
- Restructuring: Ongoing integration of Micromass and HPLC operations involves facility closures and distributor contract terminations, with further costs expected in future periods.
Investor Verification Checklist
- Verify the status and potential financial impact of ongoing patent litigation in Japan, Canada, and Europe (HP and Applera cases).
- Monitor the sustainability of HPLC consumable and service growth given the weakness in pharmaceutical instrument sales.
- Assess the impact of the $115.8 million debt load on future interest expenses and liquidity, especially if the stock repurchase program continues.
- Review the progress of the Micromass/HPLC integration to ensure projected cost savings are realized.
- Confirm the final costs associated with the environmental settlement and any future compliance expenditures at the Taunton facility.